Add on study design acceptability by the reg authorities [Regulatives / Guidelines]

posted by rahul dixit – 2010-10-26 09:08 (5726 d 09:55 ago) – Posting: # 6079
Views: 6,744

Dear All,
Greetings!
This is a very informative forum.
I wish to congratulate everyone who are sharing their knowledge and expertise using this forum.
I have came across an approved ANDA of Labetalol tablets submitted by Watson lab for US submission. Watson lab had used a study design in which 30 volunteers were enrolled (ANDA application No is 75133. Information is available on CDER)
The study conducted was crossover, two treatment, two period in which volunteers (N =30) were divided in two groups with subject 1 to 20 in group I and 21 to 30 in group II.
The dosing was done in a cross over fashion to one group first and then to second group.
As add on dsign is not acceptable in US, I am confused with this type of design.

Kindly elaborate on this.

My second query is:
In add on study design, if the result of the first group is passing, then is it necessary to carry out the dosing for the second group?
Can we divide the number of volunteers in 2:1 proportion in add on design?

Thanks and best regards
Rahul Dixit
Unichem Laboratories Ltd
India

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
310 visitors (0 registered, 310 guests [including 24 identified bots]).
Forum time: 19:03 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5